A Study of [14C]-LOXO-783 in Healthy Adult Participants
Completed · Phase 1 · NCT06102512
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $206,433
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 16
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- [¹⁴C]-LOXO-783 (drug), LOXO-783 (drug), [¹⁴C]-LOXO-783 (drug)
- Dates
- Started 2023-10-23; completion 2024-01-17
- Results posted
- Not yet
The main purpose of this study is to evaluate how much of the study drug, the radioactive substance 14C incorporated LOXO-783 (\[¹⁴C\]-LOXO-783) passes from blood into urine, feces and expired air in healthy adult participants when administered as a single dose. The study will also measure how much of the LOXO-783 and \[¹⁴C\]-LOXO-783 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts and will last up to approximately 72 and 61 days for part 1 and 2, respectively.
From ClinicalTrials.gov, last updated 2024-07-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $206,433 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fortrea Clinical Research Unit Inc $206,433
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.